Stocksigma LogoStocksigma Logo

Sudeep Pharma Q2FY27 Results and Expansion Updates

Sudeep Pharma reported a record Q2FY27 performance, with consolidated revenue rising 21% YoY to Rs 196.7 crore and EBITDA growing 32% YoY to Rs 73.2 crore

Sudeep Pharma Q2FY27 Results and Expansion Updates

Sudeep Pharma Ltd 路 Investor Presentation 路 29 Oct 2026, 1:36 am

Sudeep Pharma Q2FY27 Results and Expansion Updates Sudeep Pharma reported a record Q2FY27 performance, with consolidated revenue rising 21% YoY to Rs 196.7 crore and EBITDA growing 32% YoY to Rs 73.2 crore (margin at 37.2%, up ~70 bps). PAT rose 11% YoY to Rs 51.8 crore. For H1FY27, revenue reached Rs 355.0 crore (+23% YoY) with PAT at Rs 92.4 crore (+18% YoY). Key growth catalysts include USFDA approval for the 51,200 MT Nandesari facility and the upcoming Phase-1 25,000 MTPA battery-grade iron phosphate Dahej project targeted for completion by Mar'27.

Original exchange filing (PDF)

More announcements from Sudeep Pharma Ltd

All Sudeep Pharma Ltd announcements